Saturday, January 3, 2015

Top 10 Warren Buffett Stocks To Buy Right Now

BALTIMORE (Stockpickr) -- Stocks are bouncing hard in the second half of October. Since Monday, the big S&P 500 index has rallied 3.4%, more than doubling the broad market's year-to-date gains. That price action is starkly different from the market scenario we faced a couple of weeks ago.

Must Read: Warren Buffett's Top 10 Dividend Stocks

But don't let your guard down. Despite the recent bounce in the broad market, there are lots of big names that are starting to look "toxic" right now.

Buying big, safe blue chips doesn't make you immune from owning toxic names. In fact, every single name on our list today is a large-cap stock that's worth more than $10 billion in market value. So these aren't just names to avoid buying -- you might already own them today.

Just to be clear, the companies I'm talking about today aren't exactly junk. By that, I mean they're not next up in line at bankruptcy court. But that's frankly irrelevant; from a technical analysis standpoint, sellers are shoving around these toxic stocks right now. For that reason, fundamental investors need to decide how long they're willing to take the pain if they want to hold onto these firms in the weeks and months ahead. And for investors looking to buy one of these positions, it makes sense to wait for more favorable technical conditions (and a lower share price) before piling in.

Best European Companies To Watch For 2015: Cummins Inc.(CMI)

Cummins Inc. designs, manufactures, distributes, and services diesel and natural gas engines, electric power generation systems, and engine-related component products worldwide. It operates in four segments: Engine, Power Generation, Components, and Distribution. The Engine segment offers a range of diesel and natural gas powered engines under the Cummins and other customer brand names for the heavy-and medium-duty truck, bus, recreational vehicle, light-duty automotive, agricultural, construction, mining, marine, oil and gas, rail, and governmental equipment markets. This segment also provides new parts and service, as well as remanufactured parts and engines. The Power Generation segment offers power generation systems, components, and services, including diesel, natural gas, gasoline, and alternative-fuel electrical generator sets for use in recreational vehicles, commercial vehicles, recreational marine applications, and home stand-by or residential applications. This segment also provides components that make up power generation systems, such as engines, controls, alternators, transfer switches, and switchgears. The Components segment supplies filtration products, turbochargers, aftertreatment systems, intake and exhaust systems, and fuel systems for commercial diesel applications. This segment offers filtration and exhaust systems for on-and off-highway heavy-duty and mid-range equipment, as well as supplies filtration products for industrial and passenger car applications. This segment also develops after treatment and exhaust systems to help customers meet emissions standards and fuel systems. The Distribution segment provides parts and services, as well as service solutions, including maintenance contracts, engineering services, and integrated products. The company sells its products to original equipment manufacturers, distributors, and other customers. Cummins Inc. was founded in 1919 and is headquartered in Columbus, Indiana.

Advisors' Opinion:
  • [By Anna Prior]

    Cummins Inc.(CMI) appointed the president of its engines business, Rich Freeland, as its chief operating officer, and the company also unveiled a 25% dividend increase and the buyback of as much as an additional $1 billion of its stock.

Top 10 Warren Buffett Stocks To Buy Right Now: iShares 1-3 Year Treasury Bond ETF (SHY)

iShares Lehman 1-3 Year Treasury Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the short-term sector of the United States Treasury market as defined by the Lehman Brothers 1-3 Year U.S. Treasury Index (the Index). The Index includes all publicly issued United States Treasury securities that have a remaining maturity of between 1 and 3 years, are non-convertible, are denominated in United States dollars, are rated investment grade (Baa3 or better) by Moody�� Investors Service, are fixed rate, and have $250 million or more of outstanding face value. Excluded from the Index are certain special issues, such as flower bonds, targeted investor notes (TINs), and state and local government bonds (SLGs), and coupon issues that have been stripped from assets already included in the Index.

The Index is a market capitalization-weighted index. The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Fund�� investment advisor is Barclays Global Fund Advisor.

Advisors' Opinion:
  • [By Donald van Deventer]

    Shorter-duration Treasury Exchange-Traded Funds: (SHY), (SHV), (IEI), (BIL), (TUZ), (FIVZ), (DTUL), (VGSH), (DTUS), (DFVS), (DFVL), (SST), (ISTB), (TBZ).

Top 10 Warren Buffett Stocks To Buy Right Now: Ishares Trust S & P Global * (IXJ)

iShares S&P Global Healthcare Sector Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Standard & Poor�� Global Healthcare Sector Index (the Index). The Index is a subset of the Standard & Poor�� Global 1200 Index, and measures the performance of companies that Standard & Poor�� deems to be a part of the healthcare sector. Component companies include healthcare providers, biotechnology companies, and manufacturers of medical supplies, advanced medical devices and pharmaceuticals.

The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:
  • [By MONEYMORNING.COM]

    Consider the iShares S&P Global Healthcare Sect. (ETF) (NYSE: IXJ). While not a pure European play, it has one of the highest non-U.S. exposures in healthcare, most of which is European, and trades at a more reasonable P/E of 19. The fund is up 8.44% year to date and recently set a new all-time high, so it's definitely got momentum on its side.

Top 10 Warren Buffett Stocks To Buy Right Now: Gray Fox Petroleum Corp (GFOX)

Gray Fox Petroleum Corp., incorporated on September 22, 2011, is a domestic oil and gas exploration and development company. The Company focuses on the acquisition and exploration of oil and natural gas properties in the Western United States.

The Company has 100% working interest and an 82% net revenue interest in the 32,723 acre West Ranch Prospect. The Company�� West Ranch Prospect is located in the Butte Valley Oil Play Region of north central Nevada in Elko and White Pine Countries, which has produced over 50 million barrels of oil in Nevada from structures and reservoir horizons similar to those under the West Ranch Prospect. The prospect consists of 22 Federal leases in the Butte Valley Oil Play Region.

Advisors' Opinion:
  • [By Peter Graham]

    On Friday, small cap mining stocks Maverick Minerals Corp (OTCMKTS: MVRM) and Liberty Coal Energy Corp (OTCMKTS: LBTG) plus oil stock Gray Fox Petroleum Corp (OTCBB: GFOX) sank 30.9%, 16.67% and 11.2%, respectively. However, only one of these stocks appears to have been the subject of some kind of paid promotion in the form of an investment in some shares. So will these three small cap mining or oil stocks keep coming up empty for investors this week? Here is a closer look:

Top 10 Warren Buffett Stocks To Buy Right Now: Galectin Therapeutics Inc (GALT)

Galectin Therapeutics Inc., formerly Pro-Pharmaceuticals, Inc., incorporated on January 26, 2001, is a development-stage company. The Company is engaged in drug development to create therapies for cancer and fibrotic disease. As of December 31, 2011, the Company has two compounds in development, one is to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from different natural starting materials, both possessing the property, which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, the Company's product candidate for cancer therapy, is a linear polysaccharide polymer consisted of mannose and galactose that has a defined chemical structure and is derived from a plant source. GR-MD-02, the Company's product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source.

GM-CT-01 has in development for the therapy of colorectal cancer and is in a Phase I/II clinical trial as a combination therapy with a tumor vaccine in patients with advanced melanoma. Based on the completed Phase I and partially completed Phase II clinical trials, the Company is exploring two additional potential indicia for the use of GM-CT-01 in combination with cancer chemotherapy. There are two additional pathways for the development of GM-CT-01 for use in treatment of cancer. GM-CT-01 was found to be generally safe when studied in a Phase I clinical trial in end-stage cancer patients with multiple tumor types alone and in combination with 5-Fluorouracil (5-FU), which is an Food and Drug Administration (FDA)-approved chemotherapy used for treatment of various types of cancer.

Advisors' Opinion:
  • [By Roberto Pedone]

     

    Galectin Therapeutics (GALT) offers drug research and development to create new therapies for fibrotic disease and cancer. This stock closed up 9.6% to $12.06 in Monday's trading session.

     

    Monday's Volume: 674,000

    Three-Month Average Volume: 222,171

    Volume % Change: 149%

     

    Shares of GALT jumped higher on Monday after Ascendiant initiated coverage on the stock with a buy recommendation.

     

     

    From a technical perspective, GALT spiked sharply higher here with strong upside volume. This stock has been uptrending for the last three months, with shares ripping higher from its low of $3.95 to its recent high of $13.21. During that move, shares of GALT have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GALT within range of triggering a near-term breakout trade. That trade will hit if GALT manages to take out Monday's high of $12.44 and then once it clears its 52-week high at $13.21 with high volume.

     

    Traders should now look for long-biased trades in GALT as long as it's trending above some near-term support levels at $11 or at $10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 222,171 shares. If that breakout hits soon, then GALT will set up to enter new 52-week-high territory above $13.21, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $16.

     

Top 10 Warren Buffett Stocks To Buy Right Now: HSN Inc. (HSNI)

HSN, Inc., an interactive multi-channel retailer, provides retail experiences through various platforms, including television, online, mobile, catalogs, and retail and outlet stores. It markets and sells a range of third party and private label merchandise primarily in the United States. The company�s HSN segment offers jewelry, apparel and accessories, beauty and wellness products, housewares, home fashions, electronics, culinary, and fitness and other products directly to consumers through television home shopping programming broadcast on the HSN television networks, HSN.com Website, its mobile applications, and outlet stores. Its Cornerstone segment provides home furnishings, including indoor/outdoor furniture, window treatments, and other home related goods under the Frontgate, Ballard Designs, Grandin Road, and Improvements brands; and apparel and accessories under the Garnet Hill, TravelSmith, and Chasing Fireflies names through various branded catalogs and related Web sites. As of February 21, 2013, this segment distributed approximately 300 million catalogs; and operated 8 separate digital sale sites, and 11 retail and outlet stores. HSN, Inc. was founded in 1981 and is headquartered in St. Petersburg, Florida.

Advisors' Opinion:
  • [By Lawrence Meyers]

    Diller then spins off some of these entities into public companies, as he did with Home Shopping Network (HSNI) and timeshare company Interval Leisure Group (IILG). The company�� 52 week high was $80.64, it trades right now at $66. I�� love to make this one of my stocks to buy in the below the $50 mark, but IACI would be a bargain under $55.

Top 10 Warren Buffett Stocks To Buy Right Now: AbbVie Inc (ABBV)

AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products.

AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Advisors' Opinion:
  • [By Dividend]

    AbbVie (ABBV) has a market capitalization of $67.08 billion. The company employs 21,500 people, generates revenue of $18.380 billion and has a net income of $5.275 billion. AbbVie�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $7.614 billion. The EBITDA margin is 41.43 percent (the operating margin is 31.65 percent and the net profit margin 28.70 percent).

  • [By John Divine]

    Pharma company AbbVie (NYSE: ABBV  ) was the day's second-biggest decliner, with shares falling 4.2%. AbbVie specializes in producing drugs that treat autoimmune disorders, and today, the European Medicines Agency approved two knockoff medications that treat autoimmune diseases, effectively increasing the competition AbbVie faces in Europe.�

No comments:

Post a Comment